Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force

Scheire, Sophie;Lourijsen, Evelijn;Blauwblomme, Manon;Dib, Maria;Mullol, Joaquim;et.al.
(2026) Allergy — Vol. 0, p. 1-36 (2026)

Files

Meta-Analysis on ther Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma An EAACI Task Force.pdf
  • Open Access
  • Adobe PDF
  • 3.63 MB
Download

Details

Authors
  • Scheire, Sophieorcid-logoPharmaceutical Care Unit, Faculty of Pharmaceutical Sciences Ghent University Ghent Belgium
    Author
  • Lourijsen, Evelijnorcid-logoDepartment of Otorhinolaryngology Amsterdam University Medical Center Amsterdam the Netherlands
    Author
  • Blauwblomme, ManonDepartment of Head and Skin, Upper Airways Research Laboratory Ghent University Ghent Belgium
    Author
  • Dib, Mariaorcid-logoDepartment of Otorhinolaryngology, Head and Neck Surgery Greifswald University Medical Center Greifswald Germany
    Author
  • Mullol, Joaquimorcid-logoRhinology Unit and Smell Clinic, ENT Department, Hospital Clínic Barcelona, FRCB‐IDIBAPS Universitat de Barcelona, CIBERES Barcelona Catalonia Spain
    Author
  • et. al.
Show more
Abstract
Systemic glucocorticosteroids (sGCS) are widely used in the treatment of chronic inflammatory airway diseases such as rhinitis, rhinosinusitis and asthma. It is well-known that systemic use is linked to multiple adverse effects (AEs) both in the short-and the long-term. However, less is known about the safety of multiple short courses of sGCS. Currently there is no established agreement on the acceptable cumulative exposure to sGCS, considering the potential for various AEs. This systematic review and meta-analysis evaluated sGCS-related AEs in both upper and lower inflammatory airway disease, with a particular focus on short-and long-term risks. We further evaluated whether a dose-response relationship existed between the daily and cumulative dosages of sGCS and the occurrence of those AEs. Our meta-analysis confirmed that cumulative dosages between 500 mg and 1 g prednisolone-equivalent significantly increase the risk of most AEs, with risks increasing with incremental dose. These findings underscore the importance of: (a) judicious sGCS prescription and need for steroid stewardship, due to their potential for short-and long-term complications, occurring even with repeated short courses, and (b) prioritization of steroid-sparing approaches (e.g., biologicals) to avoid reaching a cumulative dose of 500 mg.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Scheire, S., Lourijsen, E., Blauwblomme, M., Dib, M., Agache, I., Bachert, C., Boussery, K., Chaker, A., Colman, R., Del Giacco, S., Eguiluz‐gracia, I., Fokkens, W., Gane, S., Hellings, P., Hopkins, C., Klimek, L., Maldonado, M., Maza‐solano, J., Mösges, R., et al. (2026). Meta‐Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force. Allergy, 0, 1-36. https://doi.org/10.1111/all.70332 (Original work published 2026)